Trial Profile

Evaluation of the safety and pharmacokinetics and determining the maximum tolerable dose with the use of antitumor peptide CIGB-552 in solid tumors. Phase I.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CIGB 552 (Primary)
Indications Cancer metastases; Solid tumours
Focus Adverse reactions; First in man
Acronyms ARGOS-1

Most Recent Events

15 Sep 2021 Status changed to completed, according to Results published in the International Journal of Cancer
15 Sep 2021 Results published in the International Journal of Cancer
29 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com